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This paper examines key considerations for the successful integration of genomic
technologies into healthcare systems. All healthcare systems strive to introduce new
technologies that are effective and affordable, but genomics offers particular challenges,
given the rapid evolution of the technology. In this context we frame internationally
relevant discussion points relating to effective and sustainable implementation of genomic
testing within the strategic priority areas of the recently endorsed Australian National
Health Genomics Policy Framework. The priority areas are services, data, workforce,
finances, and person-centred care. In addition, we outline recommendations from a
government perspective through the lens of the Australian health system, and argue
that resources should be allocated not to just genomic testing alone, but across the five
strategic priority areas for full effectiveness.
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INTRODUCTION
Genomic testing applications across the human life cycle are continually developing. Genomic
testing in healthcare includes the testing of specific genes (technically “genetic testing”) as well
as the sequencing of entire genomes and the incorporation of genomic information into disease
risk. The use of genomic information to inform healthcare is becoming increasingly common.
Associated with these emerging technologies is the potential for growth of prognostic, predictive,
diagnostic, and pharmacogenomic testing and screening, which can have relevance at multiple life
stages (1). However, access to and governance of these potentially beneficial testing applications
varies, with some already being embedded into national, publicly funded health systems while
others are offered only in some jurisdictions, only in the private sector or directly to consumers.
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Given the advent of genomic testing within these diverse
health settings, leadership and coordination is required to
ensure the safe and equitable delivery of genomic testing both
within and across governmental borders. In the context of the
decreasing cost of genomic technologies and their increasing
relevance to healthcare, many countries have been restructuring
their clinical genetics services to prepare for increasing demand
(2–4). International collaboration and communication will be
important in order to leverage the lessons learned around
sustainable and equitable integration of genomic technology
internationally (5). This is particularly true for some of the
more universal issues in genomics, such as the availability
and implementation of comprehensive and relevant genomic
reference databases (5). The successful leveraging of genomic
technology to improve healthcare will require a widespread,
cohesive and collaborative approach.
Herein, we describe necessary aspects for countries to consider
for enabling optimal harnessing of genomic technology for
healthcare. We do this by framing discussion around the
Australian healthcare system (described in Box 1). Australian
governments recently developed the National Health Genomics
Policy Framework (NHGPF) (10) in recognition of the need
for a collaborative approach to the utilisation of genomic
technology across the health system. The NHGPF was developed
in consultation with the general public and various other
stakeholders. The framework was endorsed in November 2017
by the Council of Australian Governments (COAG) Health
Council, and delivers a strong and coherent structure fromwhich
to coordinate activities across jurisdictions. This framework
also represents a shared commitment to implement genomic
technology into health systems for the benefit of all Australians.
The vision of the NHGPF is “helping people live longer and
better through appropriate access to genomic knowledge and
technology to prevent, diagnose, treat and monitor disease” (6, p.
5). The mission of the NHGPF is “to harness the health benefits
of genomic knowledge and technology into the Australian health
system in an efficient, effective, ethical and equitable way to
improve individual and population health” (6, p. 5). The NHGPF
represents the first national collaboration for health genomics at
the whole-of-government level in Australia.
The NHGPF reflects that for any country to achieve a health
system that effectively integrates advances in medical technology
such as genomic testing, consideration needs to be given to
how to facilitate transparent decision-making, equitable access,
provision of a suitable workforce, and effective services that can
undergo expansion and redesign (11). This must occur with the
support of rigorous assessment of evidence (12) and adequate
infrastructure, and in a financially responsible and sustainable
manner (10). Successful implementation of expanded genomic
medicine services will also take into account the genomic literacy
of the whole population, including the nuances of social and
cultural norms around the acceptance of genomic information in
healthcare (13). These requirements are outlined in the NHGPF’s
five strategic priority areas of services, data, workforce, financing,
and person-centred care.
For countries to ensure universal access and equity of
appropriate healthcare are met, an overarching national
framework such as the NHGPF for genomics decision-making
is necessary. However, governments, as well as local health
service providers, must support such a framework to ensure
effective, safe and equitable implementation of genomics into
health services (3, 10). In this context, we outline some of
the key activities for governments based on the five strategic
priority areas outlined in the NHGPF, in relation to sustainable
integration of genomic testing in healthcare.
GENOMIC SERVICES
Government health departments have a responsibility to ensure
that genomic tests supplied in their health system are safe and
effective for the target population. Genomic testing involves not
only a laboratory testing component, but involves associated
upstream and downstream services including information
provisioning, counselling, interpretation of test results, and
clinical decision-making. Implementation of genomic testing
into a health system therefore requires consideration of
these additional services in alignment with evidence-based
best practice. In addition, implementation of genomic testing
should be nationally consistent to ensure that all patients
have access to the same high quality care. This will require
appropriate governance and guidance around safety and quality
of services, development of nationally consistent guidance, inter-
jurisdictional and international coordination, rigorous processes
for assessing the utility of genomic tests, transparent decision-
making and timely monitoring and evaluation.
The importance of governance of genomic technology in
Australia was recognised more than 15 years ago, when the
Australian Government commissioned an inquiry into the use
of genomic information. The inquiry was conducted by the
Australian Law Reform Commission and the National Health
andMedical Research Council (NHMRC). The initial outcome of
the inquiry was a report entitled Essentially Yours: The Protection
of Human Genetic Information in Australia (Essentially Yours
inquiry) (14). Some of the most relevant recommendations
from the inquiry related to the regulatory framework around
access to genomic testing, and ensuring privacy and security
of genomic information. Changes resulting from the inquiry
included amendments to the Therapeutic Goods Act 1989 to
consider all genomic tests, including predictive tests, as in vitro
diagnostic devices that are regulated by the Therapeutic Goods
Administration. These legislative changes ensure that standards
around the quality, safety and efficacy of genomic tests are met
before supply by pathology laboratories.
Another key recommendation was the formation of a “Human
Genetics Commission of Australia.” The government response
at the time was to create a principal committee of the
NHMRC, namely the Human Genetics Advisory Committee,
who were responsible for implementing the recommendations.
The Committee developed national guidelines on genomic
testing in medical practice (2010), direct to consumer genetic
testing (2014) and translating complex “-omics” tests into
healthcare, including genomic tests (2015) (15–17). However,
the principal committee was ceased in 2015. Functions of the
proposed Human Genetics Commission that remain highly
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BOX 1 | The Australian health system and the funding of health-related genetic and genomic testing.
The Australian health system is unique. Six State and two Territory Governments, along with the Commonwealth Government are responsible for different aspects
of healthcare delivery to citizens, coupled with both public and private healthcare arrangements (6). The Australian health insurance agency, Medicare, provides
government funded universal access to healthcare for all Australians. Through this system, specific tests and treatments that have been approved for a Medicare
Benefits Schedule (MBS) rebate are provided to patients at no direct cost.
In addition, people can augment their healthcare with privately paid health cover. However, through this private system there is no guarantee that any additional
diagnostics and treatments are covered. Health insurance can allow for patients to choose their specialists and healthcare facility, and the agency covers many of
these fees. However, insurance companies generally only subsidise genomic tests when a patient is admitted to a hospital, and only if these tests are already covered
by the MBS. In 2016, the cost of Medicare-funded genetic and genomic tests was AU$43.5 million, with the value having increased by 24% since 2012 (7). This
funding accounts for fewer than 30 genetic and genomic tests, in contrast to the approximately 1,700 such tests that are currently performed by laboratories in
Australia (8) at a cost to State or Territory Governments, private healthcare providers, or consumers. Currently, there is no systematic data collection that identifies
which tests are funded through these various sources. Perhaps it is due to the extensive process involved in applying for MBS funding for genomic tests and the
rapid development of such tests that many are not funded through Commonwealth Government channels. Similar fragmented provision of genomic services occurs
in Canada (9).
relevant for the governance of genomics in the healthcare sector,
include (i) providing on-going advice on emerging issues; (ii)
development of policy statements and national guidelines; (iii)
identifying genetic tests that require special consideration; and
(iv) developing practice guidelines for genetic counselling and
genetic testing. These functions should be re-considered under
the new NHGPF to guide implementation of genomic testing in
healthcare, considering the changes in the regulatory landscape
that have occurred since the inquiry.
Governance and Decision-Making Around
Genomic Tests
There is a standardised process in Australia for assessing the
safety and quality of tests when applying for public funding
through the national health insurance scheme, Medicare. For
a test to qualify for public funding through the Medicare
Benefits Schedule (MBS) an application has to be made to the
Medical Services Advisory Committee (MSAC) and the test
included on the Australian Register of Therapeutic Goods. The
MSAC evaluation process is robust and extensive and involves
an assessment of the clinical validity, clinical utility and cost-
effectiveness of the test (18). Although many of the safety and
quality issues for genomic testing are similar to other types of
medical tests, some issues are intensified in the case of genomic
testing, and issues may differ depending on the target population
or purpose of the test (1). For example, a genomic test may be
less effective for population-based screening compared to use as
a diagnostic test in a symptomatic individual (1, 19). Therefore,
additional guidance and different kinds of evidence may be
required around the appropriateness of genomic testing for these
and future purposes (20, 21).
Specific evaluation models have been developed for assessing
genomic tests, such as the ACCE model developed by the
United States of America (USA) Centers for Disease Control
and Prevention (CDC) (22). The ACCE model incorporates
Analytical validity, Clinical validity, Clinical utility and Ethical,
legal and social implications (23). A similar approach was
adopted by the United Kingdom (UK) Genetic Testing Network.
This concept has also been built on through the CDC’s Evaluation
of Genomic Applications in Practice and Prevention system
for assessing genomic tests. Key learnings from these exercises
include the difficulty associated with the heterogeneity of
genomic tests, and the importance of defining the purpose of the
test. MSAC is currently piloting Clinical Utility Cards to assess
genomic tests for predisposition to disease (24). These are based
on the Clinical Utility Gene Cards developed by EuroGentest,
which in turn were based on the ACCE model.
However, only a small percentage of currently available genetic
and genomic tests have been approved so far through the
MSAC process, with the remainder funded directly by other
parties (see Box 1). If tests are not approved through MSAC,
there are a variety of ways that people can still access tests,
including direct out of pocket payments, use of health insurance
(at the discretion of the insurer), ordering of the tests by
clinicians in public facilities with standalone budgets (such as
major hospitals) and/or via research programs or clinical trials.
The arrangements for these non-MSAC approved tests differ
widely across Australian states and territories, are confusing for
patients to navigate, and cannot be summarised simply. In Box 1,
we provide examples of some existing insurance and payment
options to highlight the fragmented nature of the system.
This complex approval process is not unique to Australia;
internationally, genomic tests typically take a long time to
be incorporated into clinical practice (25). This lag in or
lack of approvals for genomic tests may be associated with
several factors, including (i) the difficulty in gathering sufficient
translational evidence, particularly for tests that only have clinical
utility for a small number of patients (21, 26); (ii) the limitations
of the indication-specific approval process in the context of
rapidly expanding uses for genomic tests (21); (iii) the fact
that sometimes a genomic test is not currently required for
adequate clinical care; and (iv) the fact that some genomic tests
have more personal utility than clinical utility (1, 20). This can
be particularly problematic when genomic diagnostic tests are
needed to inform novel treatment options for individuals with
no existing treatment options or rapid progression of disease (1).
Complementary governance frameworks, additional to existing
assessment and approval processes, might be necessary to
ensure that genomic tests can be evaluated and funded in a
timely manner.
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National and International Coordination and
Standardisation
Given the large number of genomic tests that are funded
outside of the MBS, coordination and standardisation across
jurisdictions is critical for ensuring transparent and equitable
decision-making around genomic testing, whilst accounting for
local differences in infrastructure. Coordination across states and
territories will enable pooling of expertise across jurisdictions,
which is particularly important for providing services to people
living with rare genetic conditions. Strategic investment into
translational research to inform assessment of the benefits
and harms of genomic tests for specific population cohorts
is required (27–29). In particular, this will help to expand
the benefits of genomic technology to different population
groups, beyond rare genetic conditions to more common
conditions. National networks that identify specific (e.g., gene-,
disease-, and/or technology-specific) genomic testing hubs and
facilitate coordination of evidence gathering could improve
the speed of translation of new genomic tests into clinical
practice. Many of these networks already exist in Australia,
such as the Australian Genomics Health Alliance (AGHA)
and the recently announced Australian Genomic Cancer
Medicine Program (30–32). These research collaborations aim
to bring together separate parties working toward the same
goal, being equitable and effective genomic healthcare for
all Australians.
International coordination of genomics policy, particularly
in public health, was recognised recently at an international
meeting of experts (33). A recent survey of European Union
member states revealed that 63% had a policy on genomics
in healthcare and 83% of those with a policy had developed
specific guidelines (33). In 2018, 13 European countries declared
that they will cooperate in cross-border sharing of genomic
data, through sharing of infrastructure and expertise (34). A
similar international model already exists to help find a diagnosis
for people living with rare genetic conditions, the Matchmaker
Exchange (35). These international models involve the alignment
of policies, data sharing agreements and interoperability of
data systems, through federated networks that preserve data
governance arrangements for members.
Similar models could be developed across State and Territory
Governments to achieve coordinated clinical implementation
of genomic testing and ensure equity, sustainability and
maximisation of benefits from genomic healthcare initiatives
within the public health system. To date, although State and
Territory Governments fund many genomic tests, there has
been no formal mechanism for governments to strategically
coordinate investment to support the implementation of
genomic testing in health systems. This means there is
an opportunity for further standardisation of decision-
making around genomic testing under the NHGPF (36),
that works with and complements the existing processes.
Consistency in the implementation of genomic testing across
the health system is important to ensure all patients receive
access to the same high quality healthcare. In Australia
this could be achieved through a mechanism to develop
standardised policies and/or guidelines aligned with the
NHGPF; however this will require further commitment at
all levels of government and appropriate engagement with
key stakeholders.
In Australia, some other pathology tests are funded by State
and Territory Governments, such as the biochemical tests used
for the Newborn Bloodspot Screening Programs. Australian
jurisdictions have recently developed a Newborn Bloodspot
Screening National Policy Framework [NBSNPF; (37)], which
aligns with theAustralian Population Based Screening Framework
(38), and includes a decision-making framework for the addition
or removal of conditions, including specific criteria relating
to genetic tests. Similar national standards in relation to the
development and implementation of other genomic services
and population genetic screening programs may be required in
those situations where tests are funded by State or Territory
Governments or where different evaluation models are required.
Such national guidance was one of the recommendations from
the Essentially Yours inquiry, although this is yet to be realised.
The development of these standards could benefit from learnings
from the process undertaken to develop the NBSNPF and the
ACCE model.
Classification of Genomic Tests to Inform Service
Planning and Streamline Governance
A purpose-based classification of genomic tests may help
to identify those test types that require specific evaluation
approaches, specific expertise (e.g., genetic counselling) or
specific upstream or downstream services. Identifying similarities
among certain categories of genomic tests may help to streamline
the governance and evaluation processes (26, 39). A classification
process could also inform the development of national guidelines
on what kinds of genomic tests should be provided in a health
system and by whom (40). This may include the development
of a register of approved uses for genomic tests that can be
updated over time and inform guidance for healthcare providers
(41). Information on such a register could be utilised to increase
the awareness of non-geneticists about genetic testing options
and communicate who can order specific tests. This kind of
approach has been adopted in the UK through the UK Genetic
TestingNetwork, which promotes equitable access to high quality
genomic testing across the UK (42).
Horizon Scanning, Monitoring, and Evaluation
A key function of government health departments that could
guide the development of genomic policy is the ability to monitor
genomic testing usage within health systems. Together with
appropriate horizon scanning, the ability to monitor genomic
test usage will facilitate the provision of on-going advice on
emerging issues. Such a process will help to identify which
genomic testing applications are likely to change practice in
the immediate and short term to inform key action areas for
implementing system-wide change. Although there is a national
process for assessing genomic tests for public funding in Australia
through theMBS, this process does not involve on-going, routine
monitoring to assess the usage and effectiveness of genomic tests.
There is also limited evaluation of how genomic services are
provided to ensure that healthcare providers comply with agreed
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standards (16). Close monitoring and guidance around genomic
testing is important for ensuring that the necessary infrastructure
and workforce is available in the right areas, that genomic
services are effective, and over-diagnosis and over-treatment are
prevented (12, 43).
Evaluation of genomic testing should involve assessment
of population health outcome measures including traditional
measures such as reduction of morbidity and mortality, but
also impacts on quality of life and reproductive decision-making
(20). This function is currently limited in Australia due to a
lack of national genomic testing reporting requirements. More
robust and transparent data collection on genomic testing activity
will allow governments and consumers to monitor and evaluate
this part of the healthcare system, to ensure that the use of
genomics is safe and equitable, as well as effective. Similar
data could also increase our ability to assess the wider benefits
of investing in genomic testing, through demonstrating the
outcomes of knowledge translation from rare genetic diseases to
more common, complex conditions (44). Evaluation is described
as a cornerstone for the successful translation of genomics
technology into healthcare practice, and is a key function of
public health genomics (45–48).
Currently, governments are unable to measure or monitor
direct-to-consumer testing usage and are limited in their ability
to regulate this activity. Although consumers accessing personal
genomic tests may be able to increase their health knowledge
and take action to reduce their overall healthcare burden,
there is evidence that some direct-to-consumer tests may be
inaccurate or misleading and cause undue anxiety (49) or a false
sense of complacency (50). There is a need to quantify how
many consumers are accessing genomic tests directly through
international channels, and determine the impact of this in the
Australian regulatory and service planning context. This is likely
to be a difficult task, and will require targeted research to survey
the usage of direct-to-consumer testing by Australians.
GENOMIC DATA
Infrastructure to Support Data Storage and
Sharing
The advent of new technologies has enabled rapid, massively
parallel DNA sequencing and the production of enormous
amounts of genomic data. This has occurred alongside reduced
costs of sequencing, decreasing from US$3 billion for the first
single genome, to around US$1,000 per genome in 2015 (51).
Improved affordability of genomic sequencing enables more
widespread accessibility (52), creating an urgent need for adjunct
technologies for computation and storage to cope with the
expanding demands (53). Until the early 2000s, advances in
computation and storage were occurring faster than the ability to
sequence DNA and store the respective data. However, with the
introduction of massively parallel sequencing, for the first time
the demands of genomic informatics out-paced existing models
for computation and storage (54).
The cost of sequencing has also been halving every 5 months,
much faster than the increases in informatics capacity, placing
pressure on the existing genomic informatics ecosystem (54,
55). Genomic testing, particularly massively parallel sequencing,
requires substantial computer processing infrastructure as well
as bioinformatics expertise to both design the tests and
translate raw genomic data into meaningful clinically relevant
information (56).
Given the increasing use of massively parallel sequencing
in clinical settings, it is likely that increased data storage
capacity and developments in data sharing technology will
be major enablers for the wider implementation of genomic
testing in healthcare. In particular, data storage will be a
key consideration for any proposed population-based genomic
testing program, particularly any testing that produces a large
amount of information (e.g., whole exome or whole genome
sequencing). For example, even the data from the 1,000 genomes
project in the UK has already reached 200 terabytes in size for
just 1,700 genomes (57). Storage of genomic data in Australia
is also governed by NPAAC standards, which require storage
of certain data files such as interpreted or annotated variant
files. Samples may also need to be re-analysed in the short term
in order for testing laboratories to comply with the minimum
regulatory standards. Recent developments in cloud computing
technology are facilitating the collection, use and sharing of large
datasets with reduced requirements for expensive data storage
infrastructure (58, 59).
Anticipated data requirements will need to be considered
for assessment of the minimum infrastructure needs for
implementing a genomic test in the clinical setting. The
growing application of genomic technology to all aspects of
healthcare delivery suggests that the benefits of such technology
in improving health are being increasingly recognised.
Acknowledging the mismatch between current limitations
for capacity of data storage and computation and our improving
ability to create large volumes of genomic data, there is a
necessity to address these limitations prior to implementation of
any genomic testing, particularly at a population-wide level.
Governance and Privacy of Genomic Data
Apart from infrastructure requirements, the NHGPF also
indicates a need for an appropriate level of governance around
the collection, safe storage, and sharing of national genomic
data (10). Privacy and security of genomic data are important
issues, particularly since even a small amount of “de-identified”
genomic information can become identifiable, due to the unique
nature of an individual’s DNA signature. In Australia, genomic
information is considered to be sensitive and is protected for
private health entities under the Commonwealth’s Privacy Act
1988 (Privacy Act), with each state and territory responsible for
the privacy legislation and regulation for public health agencies.
For genomic data obtained through research, compliance with
the NHMRC National Statement for Ethical Conduct in Human
Research is required to conduct research projects. Private
health entities must adhere to the Australian Privacy Principles
contained in Schedule 1 of the Privacy Act, which relates to
transparent use, collection, disclosure, quality, security and access
to personal information. Entities holding personal information
must take reasonable steps to protect information from misuse,
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unauthorised access, modification or disclosure. There are
provisions in the Privacy Act allowing genetic information to
be disclosed to family members in circumstances where this
disclosure can prevent significant harm to the individual to
whom the information relates.
While genetic information is defined as sensitive under the
Privacy Act, Australia lacks adequate legislation to protect the
privacy of genomic data and prevent genetic discrimination,
compared to other countries. In the USA, theGenetic Information
Nondiscrimination Act of 2008 protects the genetic privacy
of individuals by preventing insurers from requesting genetic
information. Similarly, the European Oviedo Convention on
Human Rights and Biomedicine (1997), the European Union
General Data Protection Regulation, and the Canadian Genetic
Non-Discrimination Act (2017) provide protections for the
genetic information of citizens. In contrast, protection against
genetic discrimination by life insurers in Australia is self-
regulated by the life insurance industry (60). The absence of
adequate protections for genomic information has implications
for public trust in the collection, storage, and sharing of
genomic data by government entities. This in turn may
affect research opportunities and precision medicine initiatives
enabled through national and international data collection
and sharing.
The need for appropriate legislation and mechanisms to
support the secure storage of genomic data was highlighted
by the recent, controversial introduction of the My Health
Record system in Australia. My Health Record is a national
electronic health record for all Australians, except those
who choose to opt out. This system is capable of storing
genomic pathology reports; however, the decision to include
genomic data on My Health Record was made without public
consultation and seemingly without due consideration of the
unique ethical issues pertaining to genomic information, given
that this information is heritable in nature (61). Questions
have arisen around the security of the system, as well as
the ability of government agencies to access health records,
and have raised concerns among health professionals and the
public. A national, population-based electronic health record
has enormous potential for furthering genomic research efforts.
However, equally, a lack of transparency and appropriate
consultation could permanently damage public trust and
participation in the system. Therefore, further consideration is
required around ethical issues and appropriate safeguards, as well
as robust public consultation, before genomic data is uploaded
onto the My Health Record system.
GENOMICS HEALTHCARE WORKFORCE
The current skillset required to deliver genomic healthcare
is broad and varied depending on the application of testing.
Generally, some or all of the following professionals may
be involved: laboratory scientists, clinical pathologists,
bioinformaticians, clinical geneticists, genetic counsellors,
and non-genetics healthcare professionals. The genomics
healthcare workforce must have adequate genomics literacy to
know when to order genomic tests; how to interpret genomic
tests to inform clinical decision-making; how to counsel
patients on genetic conditions and genomic tests; how to obtain
informed consent before a test or procedure; and how to ensure
understanding and appropriate action following a test result or
procedure (62). These aspects of genomic clinical expertise can
be broadly categorised into two distinct domains: (i) clinical
gatekeeping (ordering and interpreting genomic tests, including
clinical utility), and (ii) counselling and consent.
Generally, genomic tests warrant a greater level of expertise
than other medical tests and the provision of professional
genetic counselling around medical decision-making, including
reproductive options, due to the uncertain outcomes of
testing and implications for genetic relatives. At the very
least, the use of genomic tests requires a medical workforce
that is confident undertaking appropriate genomic risk
assessments and communicating this information to patients
(62). However, the type of model for gatekeeping genomic
testing, genetic counselling and seeking consent will depend on
the characteristics of the condition/s being tested for and the test.
As was previously noted, the ability of Australian governments
to predict demand for certain types of genomic tests is
currently limited due to the lack of a national monitoring
program. Nevertheless, there is evidence that the current model
for ordering, interpreting and providing counselling around
genomic tests is not feasible even if there was national agreement
on their criteria (2, 63). This has been recognised for some time;
for example, the Essentially Yours inquiry recommended that
Australian governments “develop strategies to assess and respond
to the need for increased and adequately resourced genetic
counselling services” (14) and examine options for development
of genetic counselling as a profession.
Training options are limited for potential counsellors in
many Australian jurisdictions. Currently, genetic counselling is
self-regulated, with counsellors choosing to become certified
by the Human Genetics Society of Australasia (HGSA). In
2017, a working group of the HGSA was formed to explore
the issue of regulation for this profession (64). A submission
is being prepared to have genetic counselling professionally
regulated through the National Alliance of Self Regulating Health
Professions, which will facilitate consistency in practice and
ensure quality in services.
Anecdotally, there is increasing demand internationally for
complex genomic tests, particularly as part of population-wide
screening programs (65, 66) and expansion beyond the diagnostic
use of genomic testing to include screening and other uses (67).
This is already putting pressure on expert genetic workforces
(39, 68). In addition, with increasing use of somatic genomic
testing in oncology, it is possible that more patients with germline
mutations could be identified, requiring attention from clinical
genetics centres (69, 70). In this context, how can we prepare
the workforce for an inevitable increase in the use of genetic
information in managing patient care? It may be necessary to
reconsider current best practice approaches to delivering such
care, by deconstructing the workforce requirements relating
broadly to each type of genomic test. This may require a multi-
pronged approach across the whole health system.
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Clinical Gatekeeping
One approach to ensuring availability of an appropriate genomics
workforce is to mainstream genomics education into the core
of medical education (62). Online learning tools may help to
increase access to genomic education and facilitate sharing of
efforts nationally and internationally (5). Without appropriate
education, there is a limited ability for non-geneticist specialists
to know which patients could benefit from more complex
genomic testing (12, 62, 71).
Alternative scenarios include general practitioners, specialist
(non-geneticist) clinicians and even pharmacists directly
ordering genomic tests from pathology providers to inform the
clinical management of their patients (72–75). Nevertheless,
genetic specialists have expressed concerns over the ability of
non-genetic clinicians to order particular genomic tests, due to
a potential lack of knowledge and understanding required for
informed consent and reporting of results (75). Additionally,
some genomic tests offered by international laboratories are
available direct to consumers, often bypassing healthcare
professionals as gatekeepers for decision-making (76). In certain
cases, these companies require a referral or review of results by a
doctor, but this may be a company employed doctor rather than
an individual’s personal doctor. A consolidated list of agreed
uses for genomic testing in general practice or specialist settings
could facilitate the mainstreaming of genomic tests, combined
with the embedding of this guidance into workflows, such as
the Health Pathways being developed by Australian primary
health networks.
Certain uses for genomic testing may be more amenable to
mainstreaming when compared to others. For example, once
clinical utility can be agreed upon, it may be appropriate
for non-genetics healthcare professionals to order certain
tests, such as pre-conception, prenatal, and diagnostic tests
and cascade screening tests for common conditions. This is
already occurring with mainstreaming of hereditary ovarian
and breast cancer testing (69, 77), and in Australia, tests
for these conditions have recently been made available to be
ordered by any healthcare practitioner under the MBS (78).
Similar mainstreaming has occurred with many (non-genomic)
medical tests, even to the point of direct consumer access
(e.g., HIV testing) (79), although this remains controversial in
many cases (80). However, mainstreaming of medical device
use will take time, as adequate training of relevant members
of the workforce will be required to ensure genomic testing
occurs in a safe and appropriate way. For example, the Public
Health Genomics Foundation in the UK has recommended
the establishment of core competencies for ordering genomic
testing (81).
In other instances, the involvement of genetic specialists
may not be easily replaced. For example, clinical geneticists,
clinical pathologists and bioinformaticians will continue to be
required for testing associated with complex rare diseases and
where whole exome or whole genome sequencing is being
used with less targeted filtering applied for analysis. Given the
dependence of implementing genomic technology on computer-
based interpretation of sequence data, there is a need to ensure
a suitably qualified bioinformatics workforce is in place to
enable translation of this information into clinically meaningful
results (47). Specific expertise is required to accurately interpret
the information in a way that can inform clinical action to
ensure the utility of genomic information in the clinical setting.
Within Australia and internationally, there are examples of
recognised super specialties and joint residencies and fellowships
in genetics for paediatric, maternal-fetal and internal medicine
specialties, and for cancer genetics and neurogenetics (62, 82).
These all acknowledge the need for genomics expertise in
particular settings.
Additional models for the gatekeeping of genomic testing
exist, and these may need to be implemented into local
programs (63). Examples include the increasing relevance of
multi-disciplinary and interdisciplinary clinics, and coordination
among health professionals in the diagnosis and management of
patients with or at risk of genetic conditions (2, 4, 71). Multi-
disciplinary teams have already been used as part of best practice
for areas such as cancer genetics and rare genetic diseases (2), and
are also being used in particular specialties such as cardiac, renal,
liver, lung, and neurology clinics. However, particularly with
gatekeeping around massively parallel sequencing technologies
applied to whole exome or whole genome sequencing, and with
increased demand for predictive and pre-symptomatic testing,
multi-disciplinary teams may become increasingly necessary in
other settings to facilitate reporting results back to individuals
(3, 71, 75).
Counselling and Consent
Generally, genetic counselling is offered where individuals or
their offspring are identified as being at higher risk than the
general population of developing a genetic condition from a
genetic or non-genetic (e.g., cholesterol) screening test, or due
to family history. Traditionally the scope of practice has been
focused on supporting people with certain Mendelian-inherited
genetic conditions. According to the Australasian Society of
Genetic Counsellors, genetic counselling is “a communication
process, which aims to help individuals, couples and families
understand and adapt to the medical, psychological, familial and
reproductive implications of the genetic contribution to specific
health conditions.” Specific functions of a genetic counsellor
include assessing risk, educating patients and families about a
genetic condition, providing guidance around decision-making,
and facilitating adjustment after a new diagnosis.
Depending on the condition, genetic counselling is usually
offered close to the time that any complex decision-making
is to occur, such as the decision to have children, undergo
pre-implantation genetic diagnosis, undergo invasive diagnostic
testing, or terminate a pregnancy when high risk for a condition
is identified or following confirmation of a diagnosis. Many
professional bodies consider the provisioning of professional
genetic counselling with all genomic tests best practice. However,
in reality if there is a substantial benefit to offering a genomic
test to a larger population, this will not be feasible to implement
and alternative models will be required where they are deemed
appropriate based on a risk assessment. A key area for the need
to find alternative models for delivery of genetic counselling
is in any application of population-wide genomic testing. For
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example, there is growing interest in introducing reproductive
genetic carrier screening for certain rare inherited conditions
where there may be no family history (e.g., recessive and X-linked
conditions) (83–85).
Lessons could be learned from similar programs or practices
such as cancer genetic counselling where demand for testing has
begun to outstrip the available supply of genetic counsellors.
For example, evidence from the USA has indicated that the
majority of women tested for BRCA1 and BRCA2 variants are
not receiving any genetic counselling (86). Alternative models
could involve mainstreaming genetic counselling among non-
genetics experts, such as genetic counselling provided by practice
nurses with a special interest in genetics (4, 87, 88), counselling
by the general practitioner or specialist, expanding the practice
of genetic counsellors outside specialist genetics centres (4), or
offering online counselling.
Preliminary evidence suggests that online delivery of
information and counselling for carrier screening is equivalent
to or non-inferior to in-person genetic counselling (89–91).
Such alternative models are considered acceptable by some peak
bodies in the USA (92). However, this approach has not been
robustly tested among a pre-conception population or among
populations with lower genomic literacy compared to research
study participants. A further alternative model for providing
pre-test genetic counselling and obtaining informed consent in
the context of increasing demand involves group counselling.
This model of service delivery has already been used in the
prenatal and cancer genetics settings (86, 87, 93, 94). Finally,
telehealth genetic counselling has been utilised extensively in
cancer genetic counselling (95), and in other settings such as
prenatal counselling (96). Recent developments in this space
include the incorporation of chatbots (artificial intelligences
with ability to converse via textual or auditory mediums) to help
triage patients (97).
FINANCING GENOMICS
Like other countries globally, Australia’s health expenditure
is increasing faster than the inflation rate, and in a climate
of budgetary constraints, there is a necessity for greater
accountability in health expenditure to create truly sustainable
public healthcare systems (98). For example, the present state of
Australia’s health systems is exemplified by Australia’s 2015–2016
ratio of health expenditure to GDP at 10.30%, up from 8.68% in
2005–2006 (99). With fragmentation of healthcare across public,
private, as well as state and commonwealth systems, the funding
arrangements for genomic testing vary for different applications
throughout the life cycle, as well as by jurisdiction.
In the context of the potential benefits of genomic technology,
governments should be investing into the basic infrastructure
and workforce required to support genomic healthcare and
should invest in clinical DNA sequencing, data storage and
computation infrastructure. Much of the investment in other
countries so far has focused on funding large-scale research
efforts, such as the 100,000 genomes project in the UK, the
All of Us precision medicine research program in the USA,
the Pilot Program for Personal Medicine in Estonia, Genome
Canada’s National Precision Medicine Initiative, and similar
projects in China, Saudi Arabia, Dubai, and Turkey. Investments
like these have involved the building of the capability for genomic
sequencing (5).
The UK and USA are ahead of most other countries in
beginning to translate the results of this research investment
into the healthcare system. Both countries have had dedicated
public health genomics centres since 1997. In June 2018, a
United States Senate Appropriations Subcommittee approved an
US$86 million increase for the All of Us precision medicine
research program, which now operates with a budget of US$376
million from the National Institutes of Health. In the UK, part of
the 100,000 genomes project included £20 million over 4 years
for a Genomics Education Programme (3), and in 2018, the
National Health Service in the UK started offering whole genome
sequencing routinely for patients with rare diseases and certain
cancers (100).
In Australia, there are a number of recent genomics
research initiatives at a state, territory and national level.
Several state-wide collaborative research entities have
been developed aimed at harnessing healthcare, industry,
and research expertise to determine how genomic testing
can be incorporated into routine clinical practice (101).
Similarly, the Australian Genomics Health Alliance, a research
project funded by the NHMRC, aims to understand and
address challenges associated with integrating genomic
medicine into Australian health systems. Genomic testing
is currently on the Commonwealth Government healthcare
agenda, as evidenced by the allocation of AU$500 million in
research funding to the Australian Genomics Health Futures
Mission (102).
Along with these research efforts, health system
implementation of genomic testing has also occurred in
recent years in Australia. For example the Western Australian
(WA) Government has a dedicated Office of Population Health
Genomics. This Office has facilitated the alignment of existing
resources within the WA health system and has developed
policy to support a rare and undiagnosed diseases diagnostic
service (103). An impact analysis of the service demonstrated a
three-fold increase in confirmed diagnostic outcomes for theWA
population. Similarly, the Victorian State Government provided
AU$8.3M for the 2017/2018 financial year to enable publicly
funded genomic sequencing for individuals with rare diseases,
along with associated genetic counselling and multidisciplinary
clinical care. Initial phases of the genomic test implementation
were reported to be delivering six times the number of disease
diagnoses compared to the previously available tests, at a quarter
of the price (104).
Australia needs further investment in embedding genomics
expertise into commonwealth and state health departments and
health services to ensure appropriate oversight and strategic
benefits realisation associated with genomic healthcare. Key
priorities for government funding in the genomic healthcare
space might include investing in a robust monitoring and
evaluation system, ensuring that appropriate sequencing
and data infrastructure is available to support increased
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demand, improving reimbursement/funding streams for multi-
disciplinary teams, and assessing cost-effectiveness of population
based genomic screening programs.
Participation in multi-disciplinary and inter-disciplinary
meetings is currently not adequately funded by the
Commonwealth Government’s activity-based funding for
hospitals. Improving the funding pathway for this activity
will be important for ensuring that genomic testing is
utilised for those patients who need it most and that
the appropriate clinical guidance is available. Processes
are underway to improve this situation, such as reviewing
current funding mechanisms to better reflect workloads (105).
Similarly, ensuring that there is adequate reimbursement that
recognises the necessary clinician time for interpretation
of test results in preparation for appointments may be
important (71).
Strategic Prioritisation of Investment
Across Different Healthcare Settings
In a public healthcare system with finite resources, prioritisation
of services is necessary (36). Agreed and consistent qualifiers to
determine prioritisation can inform allocation of resources.
One suggested approach for prioritising genomic tests
is to favour those who are at high risk of imminent,
serious, preventable conditions that are cost effective to
treat (106). Other factors to consider are the severity of
disease impact, the availability of prevention or a targeted
treatment, and acceptance of the net cost for health gains
achieved (36, 106).
Individual review of genomic tests, while necessary to
establish analytical and clinical validity, clinical utility and cost-
effectiveness, is onerous and resource intensive (36, 41). As a
result, the individual assessment of tests contributes to the ad hoc
approach to funding genomic tests in healthcare systems (9). This
is particularly the case for applications used in the context of rare
diseases and lethal conditions where limited baseline evidence is
available to inform adequate review or where time is limited due
to the progression and severity of the disease (27).
Part of the prioritisation process involves considering the
opportunity costs of investing in one healthcare service
over another, equally important service. Individual assessment
methods based on medical need do not always take into
account any comparison with investment into other services.
Higher level considerations for prioritisation of healthcare
services include maximising health gains for the population and
addressing inequities in access (36). Considering the diverse
criteria contributing to the need for genomic testing and the
need for a more strategic approach, a potential area of interest is
the development of a multi-criteria decision-making framework,
such as that developed by the UK Genetic Testing Network
(41). This framework involves ranking of genomic tests by
a group of representative stakeholders, according to weighted
criteria relating to reducing morbidity and mortality, enhancing
reproductive choice, improving the process of care, deliverability
of services and additional information (41). A similar model
could be useful in Australia.
Cost Savings
In Australia, multiple funding arrangements exist for various
genomic testing purposes creating issues for equitable access.
Given the inevitable increasing use of genomic testing in the
healthcare system, it is possible that a large proportion of the
population will eventually have at least one genomic test during
their lifetime. A cohesive approach to funding and access for
genomic testing may ultimately provide cost savings to society.
For example, for particular cohorts such as those with rare
diseases, there is the potential for whole exome, whole genome,
or targeted gene panel sequencing to produce cost savings
by avoiding a long series of other genetic tests (3). A recent
Australian study that investigated the health economic impact of
whole exome sequencing for infants with a suspected monogenic
disorder found a cost saving of AU$1,578 per quality-adjusted
life year gained at 1 year, revealing an overall cost-benefit to the
health system when genomic testing is incorporated into clinical
care for this subset of patients (107). Learnings from rare diseases
may also inform more targeted approaches to treatment for
common, complex conditions, which could translate the benefits
of reduced morbidity and mortality to the population at large,
thereby increasing the cost savings of the initial investment (44).
In contrast, the use of genomic information may lead
to increased need for healthcare services in the short term
(108), such as genomic testing indicating an increased cancer
susceptibility that encourages earlier and/or more frequent
screening and heightened vigilance that would not have occurred
in the absence of the genomic test. However, these costs may be
offset by the savings from detecting cancer early, thereby avoiding
deterioration in the patient’s condition and possibly providing a
better prognosis. This will of course depend on the availability
and effectiveness of interventions and treatments, and if test
results translate to behavioural change. Likewise, the application
of genomic testing for complex polygenic diseases may be more
cost effective if it is able to identify specific treatment options that
are more likely to be efficacious (106) and be used. An outcomes-
based approach to monitoring and evaluation will help to inform
timely and strategic funding decisions.
PERSON-CENTRED CARE
As with any new medical technology, the successful integration
of genomic medicine into healthcare delivery will rely not only
on workforce engagement in the new technology, but also on
the engagement of and acceptance by the greater population.
Adequate understanding of genomic testing by the general public
is required in order to obtain truly informed consent from
patients. Future genomic medicine initiatives will need to be
delivered in a way that is sensitive to the ethical, legal, and social
issues associated with genomic information.
Genomic Literacy in Healthcare
Consumers
Addressing public engagement and literacy in genomics is even
more important in the context of the increasing availability of
direct-to-consumer testing, although a recent study suggested
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that Australian consumers’ awareness of such tests is not as
high as would be expected based on media reports (109).
Similarly, recent surveys in the USA and UK on public
opinion on personalised medicine and genomics found that most
respondents were not familiar with these concepts (3, 110).
Successful engagement of the general public will require public
health education and promotion programs that consider the
nuances of public health behaviour change, such as the utilisation
of behavioural economics (111). This approach acknowledges
that new policies and technology alone are unlikely to catalyse
changes in health behaviours. Significant learnings can also
be drawn from the use of deliberative public engagement
methods, which have been used to explore community opinions
on similarly complex issues like biobanks (112, 113) and
personalised medicine (114). Aspects to consider that ultimately
affect an individual’s choice to engage in a health service are
strong fear of loss, considerations of the social norm, and
emotional associations (111, 115).
There are also additional implications of obtaining greater
genomic knowledge, such as the potential for perceived stigma
associated with knowing carrier status (13), psychosocial impacts
(116), negative effects on family dynamics (116), and privacy
concerns such as fear of limitations on access to insurance (109,
116). The variable perspectives on the utility of genomic testing
should also be deliberated when designing any public education
and engagement interventions. Consideration should be given
to providing educational interventions that are culturally
appropriate, including language-appropriate communication
materials (117).
Individuals in the community are likely to perceive
information from governments and independent academic
agencies to be legitimate (109). Consequently, appropriate
information produced by these organisations, such as the
NHMRC’s resources for consumers, should be utilised to educate
the general public and build acceptance in the community about
genomics in healthcare. Strong leadership from governmental
health departments will be critical to the success of raising public
acceptance of genomic healthcare (48, 118).
Equity of Access to Genomic Tests and
Their Health Benefits
The lack of existing national, state and territory policies and
procedures in Australia surrounding access to genomic testing
can lead to inequitable access. At the outset, effort should bemade
to ensure culturally appropriate genomic services are available
for all. This includes minimising any disparity due to where
people live, particularly those living in rural and remote areas,
through informed service planning and telehealth solutions. The
so called “post-code lottery” could currently result in differences
in which genomic tests are offered to individuals, if indeed
any are suggested or offered at all. Other possible areas of
inequity include a lack of appropriate reference genomes (1, 119,
120); difficulty accessing international clinical trials for people
with rare diseases; variation in access to publicly subsidised
treatment options based on traditional cancer classifications;
inequity of access to genomic tests based on ability to pay
for tests that are only available in the private sector; and
the potential for individuals with a higher education, genomic
literacy and/or financial means to more readily access direct-to-
consumer tests.
For example, currently in Australia pre-implantation genetic
diagnosis (PGD) is not publicly funded. As such, this represents
an inequity in enhanced reproductive choice for couples at higher
than usual risk of having an offspring with a genetic condition
who may wish to access such a technology to proactively
prevent their future child having or developing that specific
genetic disease/s. MSAC initially supported PGD to be publicly
funded, however on further consideration advised that it was not
appropriate forMBS listing, partly due to likely costs being largely
speculative and complexities in implementation, and requested
further information be gathered (121). Certainly providing PGD
under a publicly funded scheme would achieve the NHGPF’s goal
of providing national consistency for equity.
Like PGD, private payment for non-invasive prenatal
screening (NIPS) poses problems for equity of access when
attempting to incorporate NIPS as part of widespread uptake
into routine antenatal care. It has been estimated that with
advances in technology, the cost per NIPS test will fall under
AU$500 in the near future. However, as with PGD, any
incorporation into routine antenatal care will require a stringent
economic analysis for benefit (122) and cost utility such that
efficient and transparent allocation of public resources can
be achieved. NIPS is considered to have superior rates of
detection compared to traditional prenatal screening methods
for chromosomal abnormalities due to improved sensitivity
and specificity. This means that fewer invasive diagnostic
procedures are subsequently required, resulting in lower rates of
procedure-related miscarriage (123). However, current prenatal
screening programs that utilise ultrasound services are able
to detect structural abnormalities of the foetus that would
not be identified through NIPS, thus it is unlikely that
NIPS alone will supersede all facets of the current prenatal
screening program.
Serious consideration should be given to the infrastructure
required to ensure that genomic testing is equitably
accessible to all, and that there is culturally safe, timely
and optimised outcomes and benefits. Focused effort is
required to ensure that genomic tests are appropriate
and accessible to disadvantaged groups and underserved
populations (117). This will involve targeted research and
significant stakeholder engagement to improve translation
of genomic testing to benefit all members of the population.
This effort extends to ensuring that genetic counsellors
and other members of the healthcare workforce providing
counselling to patients have the opportunity to engage in
cultural sensitivity training. Other key priority areas for
governments include public education campaigns, developing
patient decision aids, integrating genomics into health
promotion and disease prevention programs, empowering
local community groups, and involving consumers in policy
development. Moreover, incorporation of patient-facing
interfaces in electronic medical records that contain genomic
information and are accessible to patients will help to close
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the loop and ensure that patients feel involved in their
healthcare (124).
CONCLUSIONS
A strategic, holistic, and cooperative inter-governmental
approach is needed to enable the successful integration of
genomic testing into existing healthcare systems. Such an
approach will help to prevent process duplication while also
standardising genomic test implementation across jurisdictions,
ensuring equity of access for a range of test applications, and
identifying cost-savings through shared infrastructure and
strategic planning.
The NHGPF in Australia serves as a guide, signposting
areas for consideration prior to the implementation of a
nationwide genomic testing strategy and directing key points
for discussion for the purposes of this review. Successful
implementation of the strategy is likely to require on-going
leadership and coordination around genomic healthcare from
governments and prioritisation of key healthcare settings
for implementation.
The financial impact of expanding the use of genomic
testing must be considered within the context of the NHGPF
strategic goals for ensuring the sustainability of health service
delivery, while simultaneously overcoming inequities of access,
and delivering person-centred care. All stakeholders including
the patient/individual and their family, clinicians, genomic
technology companies, geneticists, molecular pathologists,
laboratory scientists, bioinformaticians, and policymakers
should be brought together as partners to help decide the
future of genomic healthcare. However, a certain degree of
genomic literacy is required by everyone who will be involved
in such discussions, to facilitate significant engagement and
shared decisions about the application of genomic tests and
interpretation of results.
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